Table 1.
Relationships between PRKAA1 expression and the clinicopathological characteristics of patients with PC
| Characteristic | Levels | Low expression of PRKAA1 | High expression of PRKAA1 | P value |
|---|---|---|---|---|
| Age, n (%) | ≥60 | 24 (32%) | 12 (16%) | 0.001 |
| <60 | 11 (14.67%) | 28 (37.33%) | ||
| Sex, n (%) | Male | 23 (30.67%) | 27 (36%) | 0.870 |
| Female | 12 (16%) | 13 (17.33%) | ||
| Tumor size (cm), n (%) | ≤4 | 14 (18.67%) | 18 (24%) | 0.662 |
| >4 | 21 (28%) | 22 (29.33%) | ||
| Vascular invasion status, n (%) | Yes | 15 (20%) | 16 (21.33%) | 0.802 |
| No | 20 (26.67%) | 24 (32%) | ||
| Neural tract invasion status, n (%) | Yes | 23 (30.67%) | 25 (33.33%) | 0.772 |
| No | 12 (16%) | 15 (20%) | ||
| Differentiation status, n (%) | Highly differentiated | 5 (6.67%) | 7 (9.33%) | 0.164 |
| Moderately differentiated | 26 (34.67%) | 22 (29.33%) | ||
| Poorly differentiated | 4 (5.33%) | 11 (14.67%) | ||
| CA19-9 (U/ml), median (IQR) | 25.0 (12.8, 57.42) | 245.60 (101.01, 745.95) | 0.417 | |
| AFP (ng/ml), median (IQR) | 2.90 (2.01, 4.94) | 2.18 (1.73, 3.32) | 0.413 | |
| T stage, n (%) | T1+T2 | 15 (20%) | 2 (2.67%) | <0.000 |
| T3+T4 | 20 (26.67%) | 38 (50.67%) | ||
| N stage, n (%) | N0 | 22 (29.33%) | 23 (30.67%) | 0.283 |
| N1 | 11 (14.67%) | 10 (13.33%) | ||
| N2 | 2 (2.67%) | 7 (9.33%) | ||
| M stage, n (%) | M0 | 26 (34.67%) | 16 (21.33%) | 0.003 |
| M1 | 9 (12%) | 24 (37.33%) |